SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GTXi (GTXI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: former_pgs who wrote (28)5/15/2007 12:26:18 PM
From: keokalani'nui  Read Replies (1) of 85
 
I've owned it off and on since 2004--mostly on since last year. It is in my top ten.

I like the approach, the addressable markets, the institutional shareholders, the CEO and the data so far. But valuation recently made me nervous and so I donated some (was #1) to charity.

If the hgPIN trial works and the urine biomarker trial for PIN vs normal/prostatitis works (2009)--one can only dream. Company-transforming data on Acadopene for ADT is due this year and hgPIN due 1Q08. (Passed all safety hurdles 2/07.) The company presentations are outstanding.

And then of course, Ostarine, which has unexpectedly done everything right.

Notwithstanding all that, price determines whether an investment is good or bad. On that score I'm not sure where I come out today.

In short, I don't know of anything wrong here. I used to worry about the IP on Acadopene, but the company seems to have a good handle on this.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News